The Food and Drug Administration on Tuesday approved the first drug specifically for postpartum depression — a debilitating condition that affects hundreds of thousands of women a year in the United States. An estimated 400,000 women in the United States each year suffer from postpartum depression. The newly approved drug, called brexanolone, will be marketed under the name Zulresso. Sage is developing another drug to treat postpartum depression and major depressive disorder that would be administered as a once-daily pill. Earlier this month, in biggest advance for depression in years, the FDA approved esketamine, also called Spravato, for people with major depression who have not responded to other treatments.

Source: Washington Post March 19, 2019 21:52 UTC